« Return to News | Clinical Intelligence

Tasimelteon could reset body’s clock in sleep-wake disorder

Friday, January 27, 2012 02:17 PM

Vanda Pharmaceuticals’ compound tasimelteon has shown for the first time to reset the body clock and to align it to a constant 24-hour day in patients suffering from Non-24-Hour Sleep-Wake Disorder. Tasimelteon is a circadian regulator in development for the treatment of the sleep-wake disorder in completely blind individuals with no light perception.

This observation was made in four patients during the initial run-in segment of the RESET study.  RESET is a phase III study of the maintenance effect of tasimelteon in the treatment of Non-24-Hour Sleep-Wake Disorder, which affects over 50% of all completely blind individuals in the U.S. Vanda intends to enroll a total of 20 tasimelteon responders in this study.

Circadian regulation is necessary for the treatment of the disorder and is predictive of a beneficial effect on both nighttime sleep and daytime naps. While light resets the body clock in sighted individuals, keeping it synchronized with the 24-hour day, this effect is lost in completely blind individuals with no light perception.

Vanda is currently studying the efficacy of tasimelteon in Non-24-Hour Sleep-Wake Disorder in two phase III studies, SET and RESET, which are ongoing and expected to be completed by the end of 2012.

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2012 CenterWatch.